MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Author(s):: Dreno, B.; Thompson, J.F.; Smithers, B.M.; Santinami, M.; Jouary, T.; Gutzmer, R.; Levchenko, E.; Rutkowski, P.; Grob, J.J.; Korovin, S.; Drucis, K.; Grange, F.; Machet, L.; Hersey, P.; Krajsova, I.; Testori, A.; Conry, R.; Guillot, B.; Kruit, W.H.J.; Demidov, L.; Thompson, J.A.; Bondarenko, I.; Jaroszek, J.; Puig, S.; Cinat, G.; Hauschild, A.; Goeman, J.J.; Houwelingen, H.C. van; Ulloa-Montoya, F.; Callegaro, A.; Dizier, B.; Spiessens, B.; Debois, M.; Brichard, V.G.; Louahed, J.; Therasse, P.; Debruyne, C.; Kirkwood, J.M.